NUCLEOLIN and neoplasm: The conjugate is postulated to remain stable in blood circulation, whereas once delivered to tumor cells via NucA recognition to the cell surface nucleolin and taken up by endocytosis, the linker can be cleaved by lysosomal proteases in tumors, resulting in PTX release for action.